Secarna Pharmaceuticals partners with SciNeuro Pharmaceuticals
Antisense drug developer Secarna Pharmaceuticals and CNS expert SciNeuro Pharmaceuticals have inked an R&D and licence option contract for CNS diseases.
According to the agreement, Secarna Pharmaceuticals GmbH & Co KG (Planegg, Germany) will identify and validate antisense locked nucleic acid (LNA) drug candidates against multiple CNS targets provided by SciNeuro Pharmaceuticals, a player in the US and the Chinese market. SciNeuro has an option to obtain worldwide exclusive rights for development and commercialisation of all programs resulting from the collaboration. The companies did not disclose financial details about their deal.
Secarnas proprietary LNAplus platform is being applied to the discovery, testing and selection of antisense oligonucleotides (ASOs) for pre-clinical and clinical development. The platform includes the proprietary Oligofyer bioinformatics pipeline, a streamlined, high efficiency screening process, including Secarnas proprietary LNA-Vit(r)ox safety test system, as well as target-specific functional assays. Secarnas platform and ASOs have been validated by numerous in-house projects as well as in several academic and industry collaborations in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases.
